How many drugs treat Cutaneous anthrax?

Drug Landscape tracks 4 marketed treatments for Cutaneous anthrax (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/cutaneous-anthrax.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cutaneous anthrax — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cutaneous anthrax (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cutaneous anthrax, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
Doxycyclin	Doxycyclin	Bulovka Hospital		72 kDa type IV collagenase, Stromelysin-1, Collagenase 3
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Cutaneous anthrax
Bulovka Hospital · 1 drug in Cutaneous anthrax
Generic (originally Pfizer) · 1 drug in Cutaneous anthrax
Karlstad University · 1 drug in Cutaneous anthrax
Pfizer · 1 drug in Cutaneous anthrax

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cutaneous anthrax:

Cite this brief

Drug Landscape (2026). Cutaneous anthrax — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cutaneous-anthrax. Accessed 2026-06-10.

Cutaneous anthrax full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing